Brodimoprim in acute respiratory tract infections.

Abstract

Brodimoprim was studied in the treatment of acute respiratory tract infections in hospitalized, basically healthy, military conscripts. Its efficacy and tolerance were compared to those of doxycycline in a clinical randomized double-blind trial. 60 pts. were divided into two equally large groups. One group received brodimoprim, 400 mg as a loading dose followed by 200 mg daily, for 10 days. The other group received doxycycline, 200 mg as a loading dose followed by 100 mg daily, for 10 days. In the brodimoprim group, 23 patients (77%) were cured, 5 patients (16%) improved and 2 patients (6%) were considered failures. In the doxycycline group, 26 patients (87%) were cured, 3 patients (10%) improved and 1 patient (3%) did not respond. The only side effect in the whole study was moderate diarrhea in 1 patient in the brodimoprim group. Clinically and according to the normalization of laboratory values, the two drugs tested were equally effective.

• Authors: H A Salmi
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 5 Issue 6 Pg. 532-6 (Dec 1993) ISSN: 1120-009X [Print] England
• PMID: 8195852 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Trimethoprim
• Doxycycline
• brodimoprim

Topics

• Acute Disease
• Adolescent
• Adult
• Body Temperature
• Cough (drug therapy)
• Double-Blind Method
• Doxycycline (pharmacology, therapeutic use)
• Drug Tolerance
• Humans
• Length of Stay
• Leukocyte Count (drug effects)
• Leukocytes (cytology, drug effects)
• Male
• Mycoplasma Infections (blood, drug therapy)
• Neutrophils (cytology, drug effects)
• Respiration (drug effects, physiology)
• Respiratory Tract Infections (drug therapy, microbiology, physiopathology)
• Trimethoprim (analogs & derivatives, pharmacology, therapeutic use)
• Virus Diseases (blood, drug therapy)